Eloxx Pharmaceuticals, Inc. (ELOX) stock
Close on Nov 12, 2026Market cap $87.51MP/E –Yield –
Eloxx Pharmaceuticals, Inc. saw revenue fall 100.0% to $0 over fiscal 2025. At the latest close the market valued the company at $87.51M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $87.51M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.89
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $0
- Net income
- -$6.00M
- EPS, diluted
- -$0.49
- Book value per share
- $6.84
- Diluted shares
- 7M
Trading
- Previous close
- $13.01
- Open
- $12.95
- Day's range
- $12.77 – $13.00
- Volume
- 3,361
- Average volume (20 days)
- 25,654
- 52-week range
- $0.00 – $23.40
- RSI (14 days)
- 44.6
- Volatility (1 year)
- 184013.0%
- Relative volume
- 0.08×
Market cap history
Month-end market cap since 2017, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | ELOX | S&P 500 | Difference | ELOX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -7.2% | -2.7% | −4.5 pts | ||
| 3 months | -29.4% | -1.7% | −27.7 pts | ||
| Year to date | +1171718.2% | +11.9% | +1171706.3 pts | ||
| 1 year | +1288999900.0% | +12.0% | +1288999888.0 pts | ||
| 3 years | -0.7% | +78.2% | −78.9 pts | -0.2% | +21.2% |
| 5 years | -97.6% | +73.2% | −170.9 pts | -52.7% | +11.6% |
Fifteen years at a glance
Fiscal years 2010 to 2025, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Eloxx Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- News
- Results
- Results
About Eloxx Pharmaceuticals
Biological Products, (No Diagnostic Substances)
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that engages in the research and development of pharmaceutical therapies. The company focuses primarily on developing its lead drug candidate, exaluren, which is undergoing clinical evaluation. Operating through a unified research and development segment, Eloxx enters into collaborative agreements, research arrangements, and licensing partnerships to progress its drug candidates. Because its programs remain in development stages, the company currently interacts with strategic collaborators, research foundations, and commercial licensing partners, such as Almirall and the Cystic Fibrosis Foundation, rather than selling finished products directly to commercial healthcare providers.
Company profile, executives and historyEloxx Pharmaceuticals stock: common questions
What is Eloxx Pharmaceuticals's stock price?
ELOX closed at $12.89 on Nov 12, 2026, down 0.92% on the day. Over the past 52 weeks it traded between $0.00 and $23.40.
What is Eloxx Pharmaceuticals's market cap?
Eloxx Pharmaceuticals was worth $87.51M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is ELOX's P/E ratio?
Eloxx Pharmaceuticals lost money over fiscal 2025 (diluted EPS -$0.49), so it has no meaningful P/E ratio.
How much revenue does Eloxx Pharmaceuticals make?
Eloxx Pharmaceuticals reported revenue of $0 for fiscal 2025, down 100.0% from a year earlier.
Does Eloxx Pharmaceuticals pay a dividend?
No. Eloxx Pharmaceuticals has not paid a cash dividend over the last twelve months.
How has ELOX stock performed over the past year?
Including dividends, ELOX returned +1288999900.0% over the past year, against +12.0% for the S&P 500.
How many ELOX shares are sold short?
0M shares were sold short at the latest FINRA report, 2.27% of the float, or 2.1 days of average trading volume.
Who are Eloxx Pharmaceuticals's competitors?
Companies most similar to Eloxx Pharmaceuticals by business, industry and size include RLAY, MOLN, CRIS, XFOR, ACRS.
See a number that looks wrong?